REMARKS

Attached is the Request to Correct Inventorship of this non-provisional application under 37 C.F.R. 1.48(b) and (c).

In addition, Applicants are enclosing the non-patent references cited in the previous 1449 form. More specifically, Applicants are submitting the following references:

- Buchdunger et al., "Inhibition of the Abl Protein-Tyrosine Kinase *in vitro* and *in vivo* by a 2-Phenylaminopyrimidine Derivative," Cancer Research 56, pp. 100-104 (1996);
- Jürg Zimmerman et al., "Potent and Selective Inhibitors of the Abl-Kinase: Phenylaminopyrimidine (PAP) Derivatives," Bioorganic & Medicinal Chemistry Letters, Vol. 7(2), pp. 187-192 (1997);
- Stephen Byrn et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations," Pharmaceutical Research, Vol. 12(7), pp. 945-954 (1995);
- R. J. Davey et al., "Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry," J. Am. Chem. Soc., Vol. 119, pp. 1767-1772 (1997);
- H. D. Hollis Showalter et al., "Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, the Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases," Pharmacol. Ther., Vol. 76(1-3), pp. 55-71 (1997);
- Marjukka Myllärniemi et al., "Selective Tyrosine Kinase Inhibitor for the Platelet-Derived Growth Factor Receptor In Vitro Inhibits Smooth Muscle Cell Proliferation After Reinjury of Arterial Intima in Vivo," Cardiovascular Drugs and Therapy, Vol. 13, pp. 159-168 (1999);
- Radebough, Galen W., "Preformulation,"Remington: The Science and Practice of Pharmacy, 20th Edition, Chapter 83, pp. 1447-1462 (2000);

Entry of this Response is respectfully requested. Applicants believe the application is in condition for allowance.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852

Oona A. Jackson
Attorney for Applicant
Reg. No. 48,152

Date: October 12, 2005